A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma.
Death
Glioma
Ki-67
Nomogram
Recurrence
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
25
03
2024
accepted:
26
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
2
9
2024
Statut:
epublish
Résumé
This study examined to evaluate the predictive value of a nomogram with Ki-67 in overall and disease-free survival in glioma patients, a total of 76 patients diagnosed with glioma by pathology in Tengzhou Central People's Hospital were enrolled. The baseline data and follow ups were retrospectively collected from medical records. The associations between Ki-67 and survival status were examined using log-rank test, univariate and multivariate Cox proportional hazard regression models. Calibrations were performed to validate the established nomograms. Ki-67 negative group showed of a longer OS survival time and a longer PFS survival time with log-rank test (x
Identifiants
pubmed: 39223159
doi: 10.1038/s41598-024-71275-9
pii: 10.1038/s41598-024-71275-9
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20334Subventions
Organisme : Xuzhou Medical University Affiliated Hospital Development Fund Project
ID : XYFY202215
Informations de copyright
© 2024. The Author(s).
Références
Fisher, J. L. et al. Epidemiology of brain tumors. Neurol. Clin. 25(4), 867–890. https://doi.org/10.1016/j.ncl.2007.07.002 (2007).
doi: 10.1016/j.ncl.2007.07.002
pubmed: 17964019
Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359(5), 492–507. https://doi.org/10.1056/NEJMra0708126 (2008).
doi: 10.1056/NEJMra0708126
pubmed: 18669428
Westermark, B. Glioblastoma—A moving target. Ups. J. Med. Sci. 117(2), 251–256. https://doi.org/10.3109/03009734.2012.676574 (2012).
doi: 10.3109/03009734.2012.676574
pubmed: 22512247
pmcid: 3339557
Butowski, N. A., Sneed, P. K. & Chang, S. M. Diagnosis and treatment of recurrent high-grade astrocytoma. J. Clin. Oncol. 24(8), 1273–1280. https://doi.org/10.1200/JCO.2005.04.7522 (2006).
doi: 10.1200/JCO.2005.04.7522
pubmed: 16525182
Wen, P. Y. et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99–08. Clin. Cancer Res. 12(16), 4899–4907. https://doi.org/10.1158/1078-0432.CCR-06-0773 (2006).
doi: 10.1158/1078-0432.CCR-06-0773
pubmed: 16914578
Haroon, S. et al. Ki67 index in breast cancer: Correlation with other prognostic markers and potential in pakistani patients. Asian Pac. J. Cancer Prev. 14(7), 4353–4358. https://doi.org/10.7314/apjcp.2013.14.7.4353 (2013).
doi: 10.7314/apjcp.2013.14.7.4353
pubmed: 23992002
Healey, M. A. et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the nurses’ health study. Breast Cancer Res. Treat. 166(2), 613–622. https://doi.org/10.1007/s10549-017-4421-3 (2017).
doi: 10.1007/s10549-017-4421-3
pubmed: 28791482
pmcid: 6995281
Genc, C. G. et al. Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann. Surg. Oncol. 25(8), 2467–2474. https://doi.org/10.1245/s10434-018-6518-2 (2018).
doi: 10.1245/s10434-018-6518-2
pubmed: 29789972
pmcid: 6028862
Heegaard, S. S. & Helle, B. Proliferating cell nuclear antigen and Ki-67 lmmunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76(10), 1809–1813 (1995).
doi: 10.1002/1097-0142(19951115)76:10<1809::AID-CNCR2820761020>3.0.CO;2-I
pubmed: 8625052
Bredel, M. et al. High expression of DNA topoisomerase IIa and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur. J. Cancer 38(10), 1343–1347. https://doi.org/10.1016/s0959-8049(02)00065-5 (2002).
doi: 10.1016/s0959-8049(02)00065-5
pubmed: 12091064
Liu, Y. et al. Identifying Ki-67 specific miRNA-mRNA interactions in malignant astrocytomas. Neurosci. Lett. 546, 36–41. https://doi.org/10.1016/j.neulet.2013.04.030 (2013).
doi: 10.1016/j.neulet.2013.04.030
pubmed: 23643983
Okita, Y. et al. Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 29(4), 192–200. https://doi.org/10.1007/s10014-012-0084-2 (2012).
doi: 10.1007/s10014-012-0084-2
pubmed: 22331317
Hu, X. et al. Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol. Lett. 6(1), 130–134. https://doi.org/10.3892/ol.2013.1317 (2013).
doi: 10.3892/ol.2013.1317
pubmed: 23946790
pmcid: 3742817
Xu, G. et al. Correlation between preoperative inflammatory markers, Ki-67 and the pathological grade of glioma. Medicine (Baltimore) 100(36), e26750. https://doi.org/10.1097/MD.0000000000026750 (2021).
doi: 10.1097/MD.0000000000026750
pubmed: 34516487
Wang, T. et al. Molecular characteristics of thalamic gliomas in adults. J. Mol. Neurosci. 71(8), 1598–1604. https://doi.org/10.1007/s12031-021-01796-9 (2021).
doi: 10.1007/s12031-021-01796-9
pubmed: 33523385
Chen, W. J. et al. Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis. ASIAN Pac. J. Cancer Prev. 16(2), 411–420. https://doi.org/10.7314/apjcp.2015.16.2.411 (2015).
doi: 10.7314/apjcp.2015.16.2.411
pubmed: 25684464
Daniele, A. et al. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter progression free survival? A clinical and Molecular analytic investigation. Clin. Neurol. Neurosurg. 198, 106126. https://doi.org/10.1016/j.clineuro.2020.106126 (2020).
doi: 10.1016/j.clineuro.2020.106126
Wen, J. C. et al. Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis. Asian Pac. J. Cancer Prev. 16(2), 411–420. https://doi.org/10.7314/apjcp.2015.16.2.411 (2015).
doi: 10.7314/apjcp.2015.16.2.411
Cook, N. F. The glasgow coma scale: A European and global perspective on enhancing practice. Crit. Care Nurs. Clin. N. Am. 33(1), 89–99. https://doi.org/10.1016/j.cnc.2020.10.005 (2021).
doi: 10.1016/j.cnc.2020.10.005
Teasdale, G. et al. The glasgow coma scale at 40 years: Standing the test of time. Lancet Neurol. 13(8), 844–854. https://doi.org/10.1016/s1474-4422(14)70120-6 (2014).
doi: 10.1016/s1474-4422(14)70120-6
pubmed: 25030516
Gunawan, P. Y. et al. Karnofsky performance scale and neurological assessment of neuro-oncology scale as early predictor in glioma. Asian Pac. J. Cancer Prev. 21(11), 3387–3392. https://doi.org/10.31557/APJCP.2020.21.11.3387 (2020).
doi: 10.31557/APJCP.2020.21.11.3387
pubmed: 33247700
Wesseling, P. & Capper, D. WHO 2016 classification of gliomas. Neuropathol. Appl. Neurobiol. 44(2), 139–150. https://doi.org/10.1111/nan.12432 (2018).
doi: 10.1111/nan.12432
pubmed: 28815663
Fakhry, C. et al. Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer. J. Clin. Oncol. 35(36), 4057–4065 (2017).
doi: 10.1200/JCO.2016.72.0748
pubmed: 28777690
pmcid: 5736236
Go, S. I. et al. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. Tumori J. 104(4), 292–299. https://doi.org/10.5301/tj.5000694 (2018).
doi: 10.5301/tj.5000694
Paik, E. S. et al. Nomograms predicting platinum sensitivity, progression-free survival, and overall survival using pretreatment complete blood cell counts in epithelial ovarian cancer. Cancer Res. Treat. 49(3), 635–642. https://doi.org/10.4143/crt.2016.282 (2017).
doi: 10.4143/crt.2016.282
pubmed: 27669704
Zhao, Y. Y. et al. A nomogram for predicting individual prognosis of patients with low-grade glioma. World Neurosurg. 130, e605–e612. https://doi.org/10.1016/j.wneu.2019.06.169 (2019).
doi: 10.1016/j.wneu.2019.06.169
pubmed: 31319188
Gittleman, H. et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825. Neuro. Oncol. 19(5), 669–677. https://doi.org/10.1093/neuonc/now208 (2017).
doi: 10.1093/neuonc/now208
pubmed: 28453749
Arvold, N. D. & Reardon, D. A. Treatment options and outcomes for glioblastoma in the elderly patient. Clin. Interv. Aging 9, 357–367. https://doi.org/10.2147/CIA.S44259 (2014).
doi: 10.2147/CIA.S44259
pubmed: 24591820
pmcid: 3937103
Stoll, E. A., Horner, P. J. & Rostomily, R. C. The impact of age on oncogenic potential: Tumor-initiating cells and the brain microenvironment. Aging Cell 12(5), 733–741. https://doi.org/10.1111/acel.12104 (2013).
doi: 10.1111/acel.12104
pubmed: 23711239
Wiestler, B. et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: An analysis of the NOA-08 study collective. Neuro. Oncol. 15(8), 1017–1026. https://doi.org/10.1093/neuonc/not043 (2013).
doi: 10.1093/neuonc/not043
pubmed: 23595628
pmcid: 3714152
Wang, H. et al. Prognostic significance of age related genes in patients with lower grade glioma. J. Cancer 11(13), 3986–3999. https://doi.org/10.7150/jca.41123 (2020).
doi: 10.7150/jca.41123
pubmed: 32328202
pmcid: 7171497
Gallego Perez-Larraya, J. & Delattre, J. Y. Management of elderly patients with gliomas. Oncologist 19(12), 1258–1267. https://doi.org/10.1634/theoncologist.2014-0170 (2014).
doi: 10.1634/theoncologist.2014-0170
pubmed: 25342314
pmcid: 4257742
Weller, M. et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18(6), e315–e329. https://doi.org/10.1016/s1470-2045(17)30194-8 (2017).
doi: 10.1016/s1470-2045(17)30194-8
pubmed: 28483413
Goldbrunner, R. et al. The treatment of gliomas in adulthood. Dtsch. Arztebl. Int. 115(20–21), 356–364. https://doi.org/10.3238/arztebl.2018.0356 (2018).
doi: 10.3238/arztebl.2018.0356
pubmed: 29914619
pmcid: 6172648
Sun, J. et al. The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant glioma. Eur. Rev. Med. Pharmacol. Sci. 21(20), 4595–4599 (2017).
pubmed: 29131255
Wang, X. et al. Histopathological findings in the peritumoral edema area of human glioma. Histol. Histopathol. 30(9), 1101–1109. https://doi.org/10.14670/HH-11-607 (2015).
doi: 10.14670/HH-11-607
pubmed: 25780990
Maldonado, F. et al. Association between preoperative serum lactate concentrate with tumor cell proliferative index in primary brain tumor. J. Neurosurg. Sci. 66(2), 91–95. https://doi.org/10.23736/S0390-5616.19.04715-5 (2022).
doi: 10.23736/S0390-5616.19.04715-5
pubmed: 31565905
Habberstad, A. H., Gulati, S. & Torp, S. H. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas—An immunohistochemical study. Diagn. Pathol. 6, 43. https://doi.org/10.1186/1746-1596-6-43 (2011).
doi: 10.1186/1746-1596-6-43
pubmed: 21609421
pmcid: 3127815
Uematsu, M. et al. Prognostic significance of the immunohistochemical index of survivin in glioma: A comparative study with the MIB-1 index. J. Neurooncol. 72(3), 231–238. https://doi.org/10.1007/s11060-004-2353-3 (2005).
doi: 10.1007/s11060-004-2353-3
pubmed: 15937645
Abd El Atti, R. M. et al. Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors. Diagn. Pathol. 8, 126. https://doi.org/10.1186/1746-1596-8-126 (2013).
doi: 10.1186/1746-1596-8-126
pubmed: 23902708
pmcid: 3765979
Liu, J. et al. SPHK2 protein expression, Ki-67 index and infiltration of tumor-associated macrophages (TAMs) in human glioma. Histol. Histopathol. 33(9), 987–994. https://doi.org/10.14670/HH-11-995 (2018).
doi: 10.14670/HH-11-995
pubmed: 29697136
Yuan, X. et al. Significance of nuclear magnetic resonance combined with Ki-67 and VEGF detection in the diagnosis and prognosis evaluation of brain glioma. J. BUON 23(2), 410–415 (2018).
pubmed: 29745085
Yang, P. et al. Management and survival rates in patients with glioma in China (2004–2010): A retrospective study from a single-institution. J. Neurooncol. 113(2), 259–266. https://doi.org/10.1007/s11060-013-1103-9 (2013).
doi: 10.1007/s11060-013-1103-9
pubmed: 23483435